Vectibix (panitumumab) - Important Safety Information from Amgen as approved by the Irish Medicines Board 26.04.2010

Notice type: 3rd Party Publications

Date: 26/04/2010

 

Problem Or Issue:
Important Safety Information communication from Amgen on serious hypersensitivity including anaphylaxis and angiodema.

Important Safety Information - Vectibix (panitumumab)


« Back